Researcher

My Expertise

The following myeloma trials are active at Liverpool Hospital. Please contact the email below for further information and referrals.

1. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

https://clinicaltrials.gov/study/NCT05552222

2. A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

https://clinicaltrials.gov/study/NCT05519085

3. Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (M22-574 Cervino Study)

https://clinicaltrials.gov/study/NCT06158841

4. VIBER-M: a phase 1b/II study of Venetoclax, Iberdomide and Dexamethasone for patients in first or second relapse of Multiple Myeloma with t(11;14).

https://www.allg.org.au/clinical-trials-research/current-clinical-trials/

 

Keywords

Biography

Adam is a Senior Staff Specialist Haematologist at Liverpool Hospital in South Western Sydney. He is Chair of the region’s Myeloma and Plasma Cell Disorders Unit through which he and his colleagues are responsible for a large practice of patients with myeloma and related diseases. Adam has been the Principal Investigator of numerous myeloma clinical trials and is an active member of the Myeloma Working Party of the Australia Leukaemia and...view more